RECITALSWorldwide License Agreement • September 25th, 2001 • Epix Medical Inc • In vitro & in vivo diagnostic substances • New York
ContractWorldwide License Agreement • February 9th, 2022
AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho TherapeuticsWorldwide License Agreement • June 27th, 2024
EA Pharma Co., Ltd. (Head Office, Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”) and Ensho Therapeutics, Inc.（Head Office, Morris Plains, New Jersey; Founder, President and Chief Executive Officer; Neena Bitritto-Garg; “Ensho”） announced today that the two companies have signed a worldwide exclusive license agreement for the rights to develop, manufacture and commercialize novel oral inflammatory bowel disease treatments EA1080 and a portfolio of other oral selectiveα4β7 integrin antagonists for the global market excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEAN.
